Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 6, 2000, Pages 592-597

  Kyrklund, Carl ^a   Backman, Janne T ^a   Kivistö, Kari T ^a   Neuvonen, Mikko ^a   Laitila, Jouko ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A4; PLACEBO; RIFAMPICIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; MALE; RIFAMPIN; SIMVASTATIN;

EID: 0034527327     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.111414     Document Type: Article

References (31)

1. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug
2. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG-CoA reductase
3. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s
4. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
5. Clinical pharmacokinetics of mibefradil
6. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
7. The interaction of diltiazem with simvastatin
8. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
9. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
10. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients
11. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
12. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
13. Metabolism of cyclosporin A; IV: Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily
14. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
15. The nifedipine-rifampin interaction: Evidence for induction of gut wall metabolism
16. Rifampin drastically reduces plasma concentrations and effects of oral midazolam
17. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
18. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
19. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
20. Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man
21. Drug interactions in epilepsy
22. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin
23. Efficacy of statin therapy: Possible effect of phenytoin
24. Indinavir concentrations and St John's wort
25. Acute heart transplant rejection due to Saint John's wort
26. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver
27. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
28. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
29. Effect of itraconazole on the pharmacokinetics of atorvastatin
30. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
31. Updated clinical safety experience with fluvastatin